Skip to main content
Premium Trial:

Request an Annual Quote

Marina Says Initial Tox Data Shows FAP Drug to be Safe

Premium

Marina Biotech this week announced that a six-month non-human primate toxicology study of its oral familial adenomatous polyposis treatment CEQ508 has shown the drug to be safe.

FAP is an inherited, colorectal cancer syndrome characterized by the growth of colorectal polyps. Though the polyps are initially benign, they become malignant in nearly all cases in the absence of colectomy, according to the company.

CEQ508 is based on Cequent Pharmaceuticals so-called transkingdom RNAi technology, and is designed to inhibit the oncogene beta-catenin, which is expected to prevent new polyp formation and possibly slow the progression to malignancy of existing ones.

Marina picked up the drug candidate when it acquired Cequent earlier this year (GSN 4/1/2010).

In the primate study, CEQ508 was administered in an oral suspension once daily to the animals for 180 consecutive days, according to Marina. "During this period of time, no toxicity or test article related adverse events were observed."

The company noted that the toxicology study was extended by three months to support the potential requirements for a phase II trial. CEQ508 is expected to enter phase Ia/IIb testing this year.

"These interim results and the completion of the full nine-month safety study in non-human primates demonstrates the potential for the long-term treatment of patients with our novel RNAi-based therapeutic," Marina President and CEO Michael French said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more